Efficient human immunodeficiency virus (HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate

Journal of Infectious Diseases

Volumn 180, Issue 4, 1999, Pages 1122-1132

  Fang, Zhi Yu ^a   Kuli Zade, Irina ^a   Spearman, Paul ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROTEINASE; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNITY; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRION; VIRUS INFECTION; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; AVIPOXVIRUS; CELL LINE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CHICK EMBRYO; FIBROBLASTS; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; GENES, ENV; GENES, GAG; HIV-1; HUMANS; VIRION; VIRUS REPLICATION;

EID: 0033394054     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315028     Document Type: Article

References (25)

1. Heilman CA, Baltimore D. HIV vaccines-where are we going? Nat Med 1998; 4:532-4.
2. Mascola JR, Snyder SW, Weislow OS, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapter but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS vaccine Evaluation Group. J Infect Dis 1996; 173:340-8.
3. VanCott TC, Bethke FR, Burke DS, Redfield RR, Birx DL. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immunol 1995; 155:4100-10.
4. Ferrari G, Humphrey W, McElrath MJ, et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Null Acad Sci USA 1997; 94:1396-1401.
5. Belshe RB, Gorse GJ, Mulligan MJ, et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 1998; 12:2407-15.
6. Taylor J, Paoletti E. Fowlpox virus as a vector in non-avian species. Vaccine 1988; 6:466-8.
7. Taylor J, Meignier B, Tartaglia J, et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in nonavian species. Vaccine 1995; 13:539-49.
8. Konishi E, Pincus S, Paoletti E, Shope RE, Wason PW. Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens. Vaccine 1994; 12:633-8.
9. Tartaglia J, Jarrett O, Neil JC, Desmettre P, Paoletti E. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol 1993; 67:2370-5.
10. Shioda T, Shibuta H. Production of human immunodeficiency virus (HIV) like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV. Virology 1990; 175:139-48.
11. Rattier L, Vander Heyden N, Garcia J, Polinsky M, Westervelt P, Becich M. Formation of noninfectious HIV-1 virus particles lacking a full-length envelope protein. AIDS Res Hum Retroviruses 1991; 7:287-94.
12. Karacostas V, Nagashimu K, Gonda MA, Moss B. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc Natl Acad Sci USA 1989; 86:8964-7.
13. Gheysen D, Jacobs E, de Foresta F, et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 1989; 59:103-12.
14. Spearman P, Wang JJ, Vendor Heyden N, Ratner L. Identification of human immunodeficiency virus type 1 Gap protein domains essential to membrane binding and particle assembly. J Virol 1994; 68:1232-42.
15. Ferrari G, Berend C, Ottinger J, et al. Replication-defective canarypox (ALVAC) vectors effectively activate anti human immunodeficiency virus 1 cytotoxic T lymphocytes present in infected patient: implications for antigen-specific immunotherapy. Blood 1997; 90:2406-16.
16. Dong J, Hunter E. Analysis of retroviral assembly using a vaccinia/T7-polymerase complementation system. Virology 1993; 194:192-9.
17. Spearman P, Horton R, Ratner L, Kuli-Zade I. Membrane Binding of Human Immunodeficiency Virus Type 1 Matrix Protein in Vivo Supports a Conformational Myristyl Switch Mechanism. J Virol 1997; 71:6582-92.
18. Sandefur S, Varthakavi V, Spearman P. The 1 domain is required for efficient membrane binding of human immunodeficiency virus type 1 Pr55. J Virol 1998; 72:2723-32.
19. Fuerst TR, Earl PL, Moss B. Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes. Mol Cell Biol 1987; 7:2538-44.
20. Shen L, Mazzara GP, DiSciullo SO, Panicali DL, Letvin NL. Immunization with lentivirus-like particles elicits a potent SIV- specific recall cytotoxic T-lymphocyte response in rhesus monkeys. AIDS Res Hum Retroviruses 1993; 9:129-32.
21. Jenkins S, Gritz L, Fedor CH, O'Neill EM, Cohen LK, Panicali DL. Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus. AIDS Res Hum Retroviruses 1991; 7:991-8.
22. Stewart L, Schatz G, Vogt VM. Properties of avian retrovirus particles defective in viral protease. J Virol 1990; 64:5076-92.
23. Park J, Morrow CD. Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles. Virology 1993; 194:843-50.
24. Karacostas V, Wolffe EJ, Nagashima K, Gonda MA, Muss B. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology 1993; 193:661-71.
25. Dru A, Ludosky MA, Cartaud J, Beaud G. Cell line-dependent release of HIV-like gag particles after infection of mammalian cells with recombinant vaccinia viruses. AIDS Res Hum Retroviruses 1994; 10:383-90.